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Summary 
Background Single low doses of primaquine, when added to artemisinin-based combination therapy, might prevent 
transmission of Plasmodium falciparum malaria to mosquitoes. We aimed to establish the activity and safety of four 
low doses of primaquine combined with dihydroartemisinin–piperaquine in male patients in Mali.
Methods In this phase 2, single-blind, dose-ranging, adaptive randomised trial, we enrolled boys and men with 
uncomplicated P falciparum malaria at the Malaria Research and Training Centre (MRTC) fi eld site in Ouelessebougou, 
Mali. All participants were confi rmed positive carriers of gametocytes through microscopy and had normal function 
of glucose-6-phosphate dehydrogenase (G6PD) on colorimetric quantifi cation. In the fi rst phase, participants were 
randomly assigned (1:1:1) to one of three primaquine doses: 0 mg/kg (control), 0·125 mg/kg, and 0·5 mg/kg. 
Randomisation was done with a computer-generated randomisation list (in block sizes of six) and concealed with 
sealed, opaque envelopes. In the second phase, diff erent participants were sequentially assigned (1:1) to 0·25 mg/kg 
primaquine or 0·0625 mg/kg primaquine. Primaquine tablets were dissolved into a solution and administered orally 
in a single dose. Participants were also given a 3 day course of dihydroartemisinin–piperaquine, administered by 
weight (320 mg dihydroartemisinin and 40 mg piperaquine per tablet). Outcome assessors were masked to treatment 
allocation, but participants were permitted to fi nd out group assignment. Infectivity was assessed through membrane-
feeding assays, which were optimised through the beginning part of phase one. The primary effi  cacy endpoint was 
the mean within-person percentage change in mosquito infectivity 2 days after primaquine treatment in participants 
who completed the study after optimisation of the infectivity assay, had both a pre-treatment infectivity measurement 
and at least one follow-up infectivity measurement, and who were given the correct primaquine dose. The safety 
endpoint was the mean within-person change in haemoglobin concentration during 28 days of study follow-up in 
participants with at least one follow-up visit. This study is registered with ClinicalTrials.gov, number NCT01743820.
Findings Between Jan 2, 2013, and Nov 27, 2014, we enrolled 81 participants. In the primary analysis sample (n=71), 
participants in the 0·25 mg/kg primaquine dose group (n=15) and 0·5 mg/kg primaquine dose group (n=14) had 
signifi cantly lower mean within-person reductions in infectivity at day 2—92·6% (95% CI 78·3–100; p=0·0014) for 
the 0·25 mg/kg group; and 75·0% (45·7–100; p=0·014) for the 0·5 mg/kg primaquine group—compared with those 
in the control group (n=14; 11·3% [–27·4 to 50·0]). Reductions were not signifi cantly diff erent from control for 
participants assigned to the 0·0625 mg/kg dose group (n=16; 41·9% [1·4–82·5]; p=0·16) and the 0·125 mg/kg dose 
group (n=12; 54·9% [13·4–96·3]; p=0·096). No clinically meaningful or statistically signifi cant drops in haemoglobin 
were recorded in any individual in the haemoglobin analysis (n=70) during follow-up. No serious adverse events were 
reported and adverse events did not diff er between treatment groups. 
Interpretation A single dose of 0·25 mg/kg primaquine, given alongside dihydroartemisinin–piperaquine, was safe 
and effi  cacious for the prevention of P falciparum malaria transmission in boys and men who are not defi cient in 
G6PD. Future studies should assess the safety of single-dose primaquine in G6PD-defi cient individuals to defi ne the 
therapeutic range of primaquine to enable the safe roll-out of community interventions with primaquine.
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Introduction
In the past decade, great progress has been made in the 
control of malaria through widespread access to and use 
of artemisinin-based combination therapy and insecticide-
treated bednets.1 Although malaria trans mission has been 
substantially reduced,2 elimination is unlikely to be 
achieved with further scale-up of conventional methods in 
most settings in Africa.3 New tools and strategies to reduce 
malaria transmission are necessary to maintain the gains 
of malaria control and push towards elimination.4
In settings of low transmission and drug resistance, 
WHO5 recommends single doses of 0·25 mg/kg of 
primaquine as an addition to standard artemisinin-based 
combination therapy to prevent onward transmission of 
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Plasmodium falciparum infections to anopheline 
mosquitoes. Primaquine, an 8-aminoquinoline, has a 
unique drug action against mature P falciparum gameto-
cytes, the sexual stages of the parasite responsible for 
onward transmission.5 However, the widespread use of 
primaquine is hindered by safety concerns of 
dose-dependent haemolysis in people who are defi cient in 
glucose-6-phosphate dehydrogenase (G6PD). G6PD defi -
ciency is the most common inherited enzyme defi ciency 
globally and is estimated at a community prevalence of 
10–15% in much of malaria-endemic Africa, rising to much 
higher levels in certain specifi c communities.6 
Although recommendations are available, no formal 
dose-fi nding experiments have been done with a 
standardised infectivity assay to assess single doses of 
primaquine alongside artemisinin-based combination 
therapy. Recommendations are based on a review of 
historical infectivity trials7 from 158 individual gameto-
cytaemic individuals treated with plasmoquine or 
primaquine in diff erent studies with diff erent vectors 
and diff erent drug exposures. WHO’s recommendation 
was not supported by the statement “Strong recom-
mendation, high quality evidence” typical of recom-
mendations for antimalarial use, and national malaria 
control programme managers expressed reluctance to 
implement this policy until modern data were available. 
There have been no formal assessments of the effi  cacy 
of single low doses of primaquine in reducing mosquito 
infection rates when added to artemisinin-based therapy. 
The fi rst formal primaquine dose-fi nding study concluded 
that low densities of P falciparum gametocytes detected by 
molecular methods persist after single low doses of 
primaquine. That study did not test the new WHO 
recommended low dose, but concluded that 0·10 mg/kg 
was inferior to the standard 0·75 mg/kg primaquine dose 
when given in combination with artemether–
lumefantrine.8 Importantly, to our know ledge, the 
infectivity of low-density gametocytes after primaquine in 
combination with an artemisinin-based combination 
therapy has not been established. Molecular gametocyte 
detection methods could lead to false conclusions about 
residual transmission potential if these tools detect non-
transmissible gametocytes.9 Deter mination of the lowest 
effi  cacious dose of primaquine is of great importance to 
reduce the risk of dose-dependent haemolysis.10 In this 
study we aimed to establish activity for diff erent doses of 
primaquine through repeated assessments of human 
infectivity to mosquitoes alongside sensitive molecular 
gametocyte detection and quantifi cation. 
Methods 
Study design and participants
We did a single-blind, dose-ranging, adaptive randomised, 
phase 2 trial of single low doses of primaquine in boys and 
men infected with P falciparum malaria. The protocol is 
available online. This study was done in two phases (details 
in appendix p 1). In the fi rst phase, we optimised the 
membrane feeding assay and assessed three primaquine 
dose groups. The data safety monitoring committee and 
study team then reviewed the infectivity and safety results 
Research in context
Evidence before this study
We searched PubMed on Sept 18, 2015, with the terms 
“primaquine” and “malaria, falciparum”, “primaquine” and 
“gametocyte” or “primaquine” and “transmission”. We 
identifi ed no randomised controlled trials of single low doses of 
primaquine with endpoints of gametocyte or transmission 
endpoints published after the dose-fi nding study by Eziefula 
and colleagues (2014). In that study, one low dose of 
primaquine was added to artemether–lumefantrine 
combination therapy with investigators measuring duration of 
Plasmodium falciparum gametocytaemia with Pfs25 mRNA 
quantitative nucleic acid sequence-based amplifi cation 
(QT-NASBA) as the primary outcome measure for effi  cacy. The 
authors concluded that single low-dose primaquine at 
0·4 mg/kg had similar gametocytocidal effi  cacy compared with 
0·75 mg/kg, the single primaquine dose recommended by WHO 
for P falciparum until 2012, whereas they found a dose of 
0·1 mg/kg did not show non-inferiority. However, no 
assessments of transmissibility of gametocytes were done, 
which was highlighted as an important limitation. The best 
available evidence on the transmission-blocking eff ects of 
primaquine was based on infectivity data from 158 individual 
gametocytaemic individuals treated with plasmoquine or 
primaquine in diff erent studies with diff erent vectors and 
diff erent drug exposures. A pooled analysis of these data 
supported the use of primaquine at a single dose lower than 
0·75mg/kg. 
Added value of this study
To our knowledge, our study is the fi rst dose-fi nding study of 
single low-dose primaquine that uses mosquito feeding assays, 
a resource-intensive but necessary method to obtain conclusive 
infectivity assessments. In individuals with normal 
glucose-6-phosphate dehydrogenase (G6PD) enzyme function, 
doses of primaquine of 0·25 mg/kg and 0·5 mg/kg resulted in 
signifi cant decreases in infectivity to mosquitoes on day 2. Our 
fi ndings support WHO’s recommendation for single-dose 
primaquine at 0·25 mg/kg to prevent malaria transmission 
along with artemisinin-based combination therapy 
dihydroartemisinin–piperaquine.
Implications of all the available evidence
Single low doses of primaquine should be rolled out, especially 
in areas where national malaria control programme managers 
have requested that contemporary dose-fi nding studies be 
carried out. Studies are warranted on the safety of single low 
doses of primaquine in individuals who are defi cient in G6PD.
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from the fi rst phase and selected two additional primaquine 
dose groups to be tested sequentially in the second phase. 
We recruited participants from the town of Oulessebougou 
and its surrounding villages in Mali, at the Clinical 
Research Centre of the Malaria Research and Training 
Centre (MRTC) of the University of Bamako, Mali. Malaria 
transmission is high and seasonal in this setting—an 
incidence rate of about two episodes per year in children 
younger than age 5 years.11 
Inclusion criteria included male sex (to reduce the risk 
of haemolysis through incorrect classifi cation of G6PD 
status, which more commonly occurs in heterozygote 
female individuals), age of 5–50 years, having at least two 
P falciparum gametocytes per 500 white blood cells on 
thick fi lm microscopy (corresponding to ≥32 gametocytes 
per μL assuming 8000 white blood cells per μL of blood), 
a haemoglobin concentration of 80 g/L or higher, and a 
normal G6PD test result via colorimetric quantifi cation 
(OSMMR2000-D G-6-PD, R&D Diagnostics, Papagos, 
Greece). We excluded participants who had taken malaria 
drugs within 7 days of screening, had known allergies to 
the study drugs, had serious or chronic illness, or had 
diagnosed cardiac arrhythmias. All participants older 
than 18 years provided written informed consent before 
screening and enrolment. We required parental consent 
for participants younger than 18 years, with children 
aged 12–17 years also providing assent for inclusion. 
Participants were compensated for time and travel. The 
study was approved by the Ethics Committee of the 
Malaria Research and Training Centre Faculty of 
Medicine, Pharmacy and Dentistry of the University of 
Science, Techniques and Technologies of Bamako, and 
the Committee on Human Research at the University of 
California, San Francisco (UCSF).
Randomisation and masking 
Treatment allocations were randomly generated and 
assigned to a list of prespecifi ed participant identifi er (ID) 
numbers by a UCSF investigator using a computer 
program (Excel). This investigator created sealed, opaque 
envelopes with participant ID number on the outside and 
treatment allocation on the inside of the envelope. Enrolled 
participants were sequentially assigned a participant ID 
number. The site pharmacist in Mali opened the sealed 
envelope corresponding to the participant ID number and 
provided the allocated treatment regimen. In the fi rst 
phase, participants were randomly assigned (1:1:1) into 
three primaquine dose groups—0 mg/kg (control), 
0·125 mg/kg, and 0·5 mg/kg—in block sizes of six. In the 
second phase, participants were sequentially assigned (1:1) 
and enrolled fi rst into 0·25 mg/kg primaquine group and 
then into the 0·0625 mg/kg primaquine group when full. 
Block size was concealed from investigators. 
Study investigators assessing outcomes were masked to 
treatment group assignment. Participants were allowed to 
ask the study physician which treatment they received and 
so were not masked to allocation. Additionally, participants 
could have recognised the presence of primaquine through 
the bitter taste of the active pharmaceutical ingredient. 
Procedures
After collection of day 0 samples, the study pharmacist 
provided primaquine (Sanofi , Laval, QC, Canada) through 
crushing 15 mg primaquine tablets and dissolving them 
in 15 mL of drinking water. Primaquine was administered 
to the nearest mL, as described elsewhere.8 Each 
participant received an oral dose of primaquine according 
to their group assignment after a fatty snack (biscuits) to 
prevent gastrointestinal side-eff ects. All participants were 
given the fi rst tablet of a 3 day course of dihydroartemisinin–
piperaquine (Eurartesim, Sigma-Tau, Italy). Dihydro-
artemisinin–piperaquine (320 mg and 40 mg per tablet) 
was given as per manufacturer’s guidelines once a day for 
3 days with the following considerations for weight: 13 kg 
to <24 kg one tablet; 24 kg to <36 kg two tablets; 36 kg to 
<75 kg three tablets; and 75–100 kg four tablets. All 
treatment doses were directly observed by the study 
pharmacist and his assistant. 
Participants attended follow-up appointments at the 
clinic at 2 h, 6 h, 12 h, and 1 day, 2 days, 3 days, 7 days, 
14 days, and 28 days after the start of treatment. Mosquito 
infectivity was measured at day 0 (pre-treatment), day 1, 
day 2, and day 7. Venous blood was collected in heparin 
tubes kept at 37°C and placed in a membrane feeding 
system within 1 min of being collected. Three cups of 
30 Anopheles gambiae mosquitoes each (90 mosquitoes in 
total except at day 0 when 180 mosquitoes were used) 
were fed the parti cipant’s blood for 15–20 min with 
methods previously described.12 Blood-fed mosquitoes 
were then transported the next day to the insectary in 
Bamako, Mali, where they were kept until dissection on 
day 7 post-feeding and examination for oocysts in 1% 
mercurochrome. The presence of oocysts was confi rmed 
by a second microscopist. Mosquito infectivity from the 
person to the mosquito was defi ned as the proportion of 
dissected mosquitoes with oocysts. Additionally, 
participants were classifi ed as infectious (yes vs no) if at 
least one dissected mosquito had at least one oocyst.
Haemoglobin was measured before treatment (day 0) 
and at each follow-up visit (days 1, 2, 3, 7, 14, and 28) 
using HemoCue (AB Leo Diagnostics, Helsingborg, 
Sweden). Adverse events were assessed actively during 
follow-up visits (days 1, 2, 3, 7, 14, and 28) and passively 
through the availability of study clinicians 24 h per day, 
7 days per week, without charge during the follow-up 
period, including free transportation if needed. Adverse 
events were graded by severity (mild, grade 1; moderate, 
grade 2; or severe, grade 3, in intensity, and whether they 
were considered serious by the treating physician) and 
categorised by their relationship with the study drugs 
(unrelated or probably not, possibly, probably, or 
defi nitely related). Additionally, we recorded the duration 
of adverse event, any actions taken, and outcome of 
adverse events. 
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Figure 1: Trial profi le
WBC=white blood cells. G6PD=glucose-6-phosphate dehydrogenase. AE=adverse event.
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Gametocyte density measurements were done on day 0 
(pre-treatment), 2 h, 6 h, and 12 h after treatment, and on 
days 1, 2, 3, 7, 14, and 28. Blood slides stained with 
Giemsa were double read by expert research micro-
scopists over 500 fi elds for quantifi cation of gametocytes 
and asexual stages. 100 μL of whole blood was collected 
in L6 buff er (Severn Biotech, Kidderminster, UK), total 
nucleic acid was extracted using a MagNAPure LC 
automatic extractor (Total Nucleic Acid Isolation Kit–
High Performance; Roche Applied Science, Indianapolis, 
IN, USA) followed by RQ1 DNaseI digest (Promega, 
Sunnyvale, CA, USA), cDNA synthesis (High Capacity 
cDNA Reverse Transcription Kit, Applied Biosystems, 
Foster City, CA, USA), and molecular quanti fi cation of 
gametocytes using Pfs25 mRNA quantitative real-time 
(qRT) PCR, as described elsewhere.13 Gametocyte 
concentration was estimated using a reference trendline 
of cultured mature stage V gametocytes (NF54 strain14) 
that was serially diluted using tenfold dilutions from 10⁶ 
to 10 gametocytes per mL.
Genomic DNA available from total nucleic acids extracted 
for gametocyte quantifi cation were used for genotyping 
cytochrome P450 2D6 (CYP2D6). Samples from all 
participants were tested, and participants with a suffi  cient 
amount and quality of DNA were genotyped for CYP2D6 
*2, *3, *4, *6, *7, *8, *9, *10, *11, *15, *17, *18, *19, *20, 
*29, *40, and *41 alleles using Openarray technology on a 
QuantStudio 12K Flex RT PCR system (Life Technologies, 
Carlsbad, CA, USA). The CYP2D6 copy number was 
determined with a TaqMan copy number assay targeting 
intron 2 on the QuantStudio 12K Flex system, and CYP2D6 
metaboliser status was inferred from the genotypes using 
both classic and activity score methods.15,16
Outcomes 
The primary effi  cacy outcome was the mean within-person 
percentage change in mosquito infectivity per group, 
2 days after primaquine administration. Prespecifi ed 
secondary effi  cacy endpoints were the presence of oocysts 
in mosquito at other timepoints (day 1 and day 7), the 
proportion of individuals infecting at least one mosquito 
(at all timepoints), gametocyte prevalence, and density 
determined microscopically and by molecular methods, 
and asexual parasite prevalence and density. Safety 
outcomes were adverse events and haemolysis, for which 
we calculated the average within-person change in 










Age (years) 12 (7–25) 22 (7–30) 10 (8–11) 22 (7–32) 10 (7–16) 18 (8–30)
Haemoglobin (g/L) 124 (112–138) 130 (110–139) 120 (108–129) 135 (111–144) 119 (112–132) 122 (113–142)
Gametocyte density by microscopy 
(per μL)
64 (32–720) 64 (32–144) 96 (48–576) 80 (32–320) 144 (48–720) 48 (32–192)
Asexual parasite prevalence by 
microscopy
54 (67%) 8 (50%) 11 (69%) 14 (82%) 8 (53%) 13 (77%) 
Asexual parasite density by 
microscopy (per μL)*
376 (64–2128) 176 (40–3840) 1088 (144–2832) 216 (48–1264) 1656 (432–9808) 144 (32–1792)
Symptomatic malaria† 6 (7%) 0 3 (19%) 1 (6%) 0 2 (12%)
Data are median (IQR) or n (%). *Median parasite densities were calculated for parasite-positive individuals only. †Temperature ≥37·5°C and parasitaemic. 
Table 1: Baseline characteristics of participants overall and by primaquine dose group 
Reduction at day 1 Reduction at day 2 Reduction at day 7
Population assessed for infectivity (n=71)
Control group 16·2% (14·7 to 46·9); ref 11·3% (–27·4 to 50·0); ref 45·8% (11·9 to 82·2); ref
0·0625 mg/kg group 38·2% (7·4 to 68·9); p=0·17 41·9% (1·4 to 82·5); p=0·16 77·9% (55·1 to 100); p=0·050
0·125 mg/kg group 37·9% (–6·7 to 82·6); p=0·19 54·9% (13·4 to 96·3); p=0·096 66·7% (35·4 to 97·9); p=0·25
0·25 mg/kg group 80·9% (59·4 to 100); p=0·0036 92·6% (78·3 to 100); p=0·0014 93·3% (79·0 to 100); p=0·0099
0·5 mg/kg group 78·5% (54·0 to 100); p=0·0040 75·0% (45·7 to 100); p=0·014 81·5% (59·6 to 100); p=0·049
Participants who were infectious before treatment (n=57)
Control group 22·6% (–22·4 to 67·6); ref 27·5% (–22·7 to 77·7); ref 66·1% (22·7 to 100); ref
0·0625 mg/kg group 47·0% (10·2 to 83·6); p=0·18 59·3% (16·9 to 100); p=0·18 97·4% (91·7 to 100); p=0·052
0·125 mg/kg group 69·4% (21·4 to 100); p=0·057 94·9% (84·6 to 100); p=0·045 100% (100 to 100); p=0·142
0·25 mg/kg group 87·8% (70·4 to 100); p=0·014 99·2% (97·6 to 100); p=0·0082 100% (100 to 100); p=0·052
0·5 mg/kg group 91·5% (73·4 to 100); p=0·0064 87·6% (60·2 to 100); p=0·030 95·1% (84·2 to 100); p=0·11
Data are mean (95% CI), unless stated otherwise. Reduction in infectivity measured as the average change in proportion of dissected mosquitoes with oocysts.
Table 2: Average within-person percentage reduction in mosquito infectivity at day 1, 2, and 7 after treatment
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haemoglobin, the proportion of participants with a 25% or 
greater drop in haemoglobin, and the proportion of 
participants with a haemoglobin level of 80 g/L or lower 
during follow-up. As a prespecifi ed secondary analysis, we 
aimed to explore the genetics of cytochrome P450, the 
enzyme responsible for the activation of primaquine to its 
active metabolite for the cure of vivax malaria.
Statistical analysis
Sample size calculations assumed that the proportion of 
people that would infect at least one mosquito was 0·80, and 
that on average the proportion of mosquitoes that would 
become infected was 0·25. We originally calculated that we 
would need 30 participants per group to have 80% power to 
detect a 90% reduction in the number of mosquitoes with 
oocysts after treatment with a 0·05 signifi cance. However 
after assay optimisation we revisited the sample size 
calculation and found that, after allowing for 10% loss to 
follow-up, we needed 15 individuals per group. 
For the primary outcome we calculated the average 
within-person percent change in infectivity and 
accompanying 95% CI for each treatment group. To make 
pairwise comparisons of the change in infectivity and 
change in haemoglobin concentration after treatment 
(control vs each treatment group) we used the one-sided 
non-parametric Wilcoxon rank-sum test. Additionally, we 
used the one-sided exact probability test to compare the 
proportion of infectious individuals in each treatment 
group to the control group at each visit, and the one-sided 
non-parametric Wilcoxon rank-sum test to compare the 
median proportion of mosquitoes infected in each 
treatment group to the median proportion of mosquitoes 
infected in the control group at each visit. 
qRT-PCR gametocyte density and prevalence at 
individual treatment days were compared between 
individual primaquine groups and the control group using 
linear (log10 density) and logistic (prevalence) regression 
models with treatment group and baseline qRT-PCR 
gametocyte density as independent variables. qRT-PCR 
gametocyte density was used to generate the area under 
the curve (AUC) of gametocyte density versus time, which 
was compared between the treatment and control groups 
as described previously17 with log10 transformed AUC as 
dependent variable in a linear regression model with 
treatment group and baseline qRT-PCR gametocyte 
density as independent variables. The association between 
the proportion of infected mosquitoes and qRT-PCR 
gametocyte density was determined by Spearman 
correlation coeffi  cient before and after treatment. 
Analyses of gametocytes were done among all 
enrolled participants, excluding those who violated the 
protocol. Analysis of the change in infectivity (primary 
endpoint) included only patients who completed the 
study after optimisation of the infectivity assay, who 
had a pre-treatment infectivity measurement and at 
least one follow-up infectivity measurement, and who 
were given the correct primaquine dose (primary 
infectivity analysis sample). In addition, we did a 
change in infectivity analysis including only participants 
who infected at least one mosquito pre-treatment. 
Analyses of adverse events and the change in 
haemoglobin (safely endpoint) after treatment were 
restricted to participants with a pre-treatment measure-
ment and at least one follow-up visit (total enrolled 
sample with a follow-up visit). Analyses were done with 
Stata version 12.1.
A data safety monitoring committee oversaw the study, 
and the study was monitored by an external clinical trials 
monitoring group, Agence Africaine de Recherche en 
Santé Humaine. Dakar, Senegal. The study was registered 
with ClinicalTrials.gov, number NCT01743820.
Role of the funding source 
The funder of the study had no role in the data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had fi nal responsibility for the decision 
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Figure 2: Proportion (95% CI) of individuals who infected at least one mosquito (A) and proportion (median 
[line], IQR [box], and range [whisker]) of mosquitoes infected by these 57 individuals (B), by group and visit
For more on the Agence 
Africaine de Recherche en 
Santé Humaine see 
http://www.aarsh.com
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Results 
We screened 1485 individuals, enrolling 81 participants 
into the study between Jan 19, 2013, and Dec 20, 2014 
(fi gure 1, table 1). Of those screened, most were not 
eligible due to the absence of gametocytes assessed by 
microscopy (n=1159). 77 participants (95%) were retained 
through the day 28 follow-up visit; no participants were 
lost to follow-up. 
In phase one (Jan 2, 2013, to Feb 22, 2014), 16 participants 
were randomly assigned to the control group, with 
17 randomly assigned to the 0·125 mg/kg primaquine 
group and 17 to the 0·5 mg/kg primaquine group. One 
participant assigned to the 0·125 mg/kg primaquine group 
was inadvertently given 0·375mg/kg. This error was 
discovered at the day 0 visit, and the participant was retained 
in follow-up through day 28 and included in the haemo-
globin and adverse event analysis but excluded from the 
change in infectivity analyses. In phase two (Aug 5, 2014, to 
Nov 28, 2014), 15 patients were sequentially allocated to the 
0·25 primaquine group and then 16 were sequentially 
allocated to the 0·0625 mg/kg primaquine group.
The study was halted on Feb 13, 2013, after eight 
participants had been recruited because pre-treatment 
infection rates in the mosquitoes were unacceptably low. 
Assay optimisation and protocol amendments were 
completed and the study restarted enrolment on the 
Sept 17, 2013 (appendix p 1). After optimisation 79% (58 of 
73) of pre-treatment membrane feeding experi ments 
resulted in at least one infected mosquito, and 24% 
(1763 of 7301) of mosquitoes became infected. Overall, we 
used 32 040 mosquitoes in feeding experiments, of which 
24 009 (75%) survived to be dissected on day 7, resulting in 
2043 infection-positive results (appendix p 2).
The primary analysis of the change in infectivity was 
done in the 71 participants in the primary analysis 
sample. We recorded signifi cantly reduced mean within-
person infectivity on day 2 in participants assigned to the 
0·25 mg/kg (92·6% [95% CI 78·3–100; p=0·0014) and 
the 0·5 mg/kg groups (75·0% [45·7–100]; p=0·014) 
compared with the control group (11·3% [–27·4 to 50·0]; 
table 2). Among individuals who were infectious before 
treatment (infected at least one mosquito; subgroup 
sample [n=57]), within-person infectivity after treatment 
was largely reduced and signifi cantly diff ered from 
controls at day 2 in those assigned to the 0·125 mg/kg, 
0·25 mg/kg, and 0·5 mg/kg groups (table 2). 
The proportion of individuals that infected at least one 
mosquito 2 days after treatment was signifi cantly reduced 
in the 0·125 mg/kg, 0·25 mg/kg, and 0·5 mg/kg dose 
groups (fi gure 2A; appendix p 2). Analysis of the median 
number of mosquitoes infected at each timepoint by 
dose group showed signifi cantly fewer mosquitoes 
becoming infected on day 2 in dose groups 0·125 mg/kg, 
0·25 mg/kg, and 0·5 mg/kg compared with control 
group (fi gure 2B; appendix p 2). No participants in either 
the 0·125 mg/kg group or the 0·25 mg/kg group infected 
mosquitoes at day 7, and one participant in the 0·5 mg/kg 
primaquine group infected a single mosquito on day 7 
after treatment.
All study participants who received the correct dose of 
primaquine (n=80) were gametocyte positive on Pfs25 
mRNA qRT-PCR at enrolment, with a signifi cantly higher 
gametocyte density at enrolment in the 0·25 mg/kg 
primaquine group compared with the control group 
(appendix p 3; p=0·013). After adjustment for baseline 
gametocyte density, gametocyte prevalence was signifi cantly 
lower in the 0·5 mg/kg primaquine group than the control 
group on day 7, day 14, and day 28 (fi gure 3A). On day 28, 
gametocyte prevalence was lower in all participants in 
primaquine dose groups compared with the control group 
(fi gure 3A). Gametocyte density decreased during follow-up 
for all treatment groups (appendix p 3); the density of 
gametocytes in gametocyte-positive individuals was 
signifi cantly lower in groups assigned to primaquine doses 
of 0·125 mg/kg and lower from day 3 onwards, after 
adjusting for baseline density (fi gure 3B; appendix p 3). The 
AUC of gametocyte density over time was signifi cantly 
lower in all primaquine groups compared with the control 
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Figure 3: Gametocyte prevalence (A) and density (B) by Pfs25mRNA qRT PCR by visit and treatment group
Gametocyte prevalence was zero in the 0·5 mg/kg group at day 14 and day 28
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group, after adjust ment for baseline density (p≤0·027 for 
0·125 mg/kg vs control; appendix p 3). Before treatment, 
Pfs25 mRNA qRT-PCR gametocyte density was strongly 
associated with mosquito infection rates (n=73; Spearman 
correlation coeffi  cient 0·56, 95% CI 0·44–0·66; p<0·0001; 
fi gure 4, appendix p 3). This association was no longer 
apparent on day 1 (n=71; r=0·07, 95% CI –0·17 to 0·30; 
p=0·57), day 2 (n=71; r=0·17, 95% CI –0·07 to 0·39; p=0·16), 
or day 7 (n=46; r=0·15, 95% CI –0·15 to 0·42; p=0·34) after 
initiation of treatment (fi gure 4, appendix p 3).
Analyses of change in haemoglobin and of adverse 
events were restricted to participants with at least one 
follow-up visit (n=79). Overall median haemoglobin 
concentration on day 0 was 124 g/L (range 86–162), on 
day 7 was 116 g/L (range 85–179), and on day 28 was 
123 g/L (range 102–173). Within-person changes in 
haemoglobin concentration were not signifi cant in any 
of the treatment groups compared with the control 
group at any timepoint (appendix p 4). During follow-
up, no participants had a haemoglobin concentration 
lower than 80 g/L or had a 25% or greater drop in 
haemoglobin after treatment. 
42 (53%) participants had an adverse event during 
follow-up (table 3). The number of participants that had 
an adverse event did not signifi cantly diff er between 
groups (Fisher’s exact test, p=0·48). Most adverse events 
(69 [87%]) were mild (grade 1), with ten (13%) of moderate 
severity (grade 2). No adverse events resulted in stopping 
study treatment or study participation. One participant in 
the 0·5 mg/kg group reported transitory dark urine 
(mild, grade 1) on day 1, which was considered unrelated 
to study drug because this participant’s haemoglobin 
concentration was 142 g/L on day 0 and remained higher 
than this concentration until day 28. One participant in 
the control group reported shortness of breath (mild, 
grade 1), which was resolved and considered unrelated to 
study treatment. There were no severe adverse events or 
serious adverse events detected during the study, and all 
adverse events resolved during study follow-up. 
We successfully genotyped CYP2D6 DNA for 43 (53%) of 
81 participants.18 Two participants were poor metabolisers 
(one in the control group and one in the 0·0625 mg/kg 
group) and four were intermediate metabolisers by both 
conventional phenotype inference. Five were intermediate 
metabolisers by the conventional method, but extensive 
metabolisers by activity score, 30 were extensive meta-
bolisers by both the conventional method and activity 
score, and two were ultra-rapid metabolisers (one in the 
0·0625 mg/kg group and one in the 0·25 mg/kg group). 
CYP2D6 typing failed for the participant who received 
0·5 mg/kg primaquine and was infectious on day 7. 
CYP2D6 genotypes did not diff er signifi cantly between 
treatment groups (Fisher’s exact test, p=0·35). 
Discussion 
We show that although gametocytes persist on molecular 











Participants with an 
adverse event
6 (40%) 9 (56%) 10 (63%) 6 (40%) 11 (65%)
Number of adverse events 20 13 16 10 20
Number drug related* 3 0 1 0 0
Headache
Mild 2 4 1 2 3
Moderate 2 0 1 1 0
Abdominal pain
Mild 2 2 2 1 1
Fever
Mild 0 3 0 3 1
Loss of appetite
Mild 3 0 2 0 1
Fatigue 
Mild 2 0 2 0 1
Moderate 0 0 1 0 0
Cough
Mild 1 0 0 1 3
Nausea
Mild 1 0 2 0 2
Runny nose
Mild 1 0 2 1 0
Dizziness
Mild 1 1 0 1 0
Muscle aches
Mild 1 0 1 0 1
Diarrhoea
Mild 0 1 0 0 1
Respiratory infection
Mild 0 1 1 0 0
Back pain
Mild 0 0 0 0 1
Moderate 2 0 0 0 0
Burning with urination
Mild 0 0 0 0 1
Pain with urination
Mild 0 0 0 0 1
Table 3 continues on next page
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Figure 4: The association between gametocyte density and infectivity pre-treatment (A) and post- treatment (B)
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90% on day 2 and day 7 after one 0·25 mg/kg primaquine 
dose and artemisinin-based combination therapy. 
Among participants that infected mosquitoes pre-
treatment, we saw a greater than 90% reduction in 
infectivity with primaquine doses of 0·125 mg/kg or 
higher by day 2 and in all groups given single low doses 
of primaquine by day 7. We observed no serious adverse 
events or evidence of haemolysis in our study population 
of G6PD-functional boys and men.
Treatment with artemisinin-based combination therapy 
results in a rapid reduction in P falciparum gametocyte 
carriage and transmissibility. In our study, 79% of all 
participants with microscopically detectable gametocytes 
infected at least one mosquito before treatment, similar 
to fi ndings from a meta-analysis on membrane feeding 
assays.19 With dihydroartemisinin–piperaquine treatment 
alone (ie, the control group), this proportion was reduced 
to 54% by day 2 and 23% by day 7, representing reductions 
in infectivity of 27% and 66%, respectively (fi gure 2A). 
The residual transmission after dihydroartemisinin–
piperaquine treatment has been observed before20 and is 
partly explained by the limited eff ect of the artemisinin 
component against mature (stage V) gametocytes that 
were present before treatment.21 Single low doses of 
primaquine greater than 0·125 mg/kg potentiate the 
transmission-reducing eff ect of dihydroartemisinin–
piperaquine. Only one individual was infectious on day 7 
after primaquine treatment among those given doses of 
primaquine of 0·125 mg/kg or higher and this person 
infected only one mosquito. Our fi ndings of near 
complete prevention of transmission in all individuals 
given 0·125 mg/kg of primaquine or higher, when given 
in combination with dihydroartemisinin–piperaquine, 
are consistent with historical data in which primaquine 
was administered in conjunction with other antimalarial 
drugs.7 Future studies should explore whether the 
transmission-blocking eff ects of single low doses of 
primaquine depend on the type of artemisinin-based 
combination therapy they are co-administered with.
Gametocytes were detected in all treatment groups 
after treatment. Notably, the presence of gametocytes and 
gametocyte density were not associated with infectivity 
after treatment. Recent studies on the effi  cacy of single 
low doses of primaquine frequently used gametocyte 
prevalence as the primary endpoint as a surrogate for 
infectivity.22,23 In our study population most individuals in 
the control group retained low densities of gametocytes 
measured by Pfs25 mRNA qRT PCR until the end of 
follow-up on day 28. Although primaquine shows a dose-
dependent eff ect on gametocyte prevalence, there was a 
clear discordance between gametocyte prevalence and 
density estimates and the likelihood of mosquito 
infection after treatment. Before treatment, gametocyte 
densities were strongly associated with the proportion of 
infected mosquitoes, but this association was lost during 
days post-treatment. Older studies had similar fi ndings 
with gametocytes being detectable by microscopy for 
several days after primaquine but failed to infect 
mosquitoes.21 Our results support the view that available 
tests to assess gametocyte density cannot be used to 
estimate post-treatment infectivity. 
The gametocyte density and infectivity mismatch 
shown in our fi ndings might be explained by preferential 
measurement of female gametocytes in our methods. 
Pfs25 mRNA transcripts, which we used to measure 
gametocytes in this study, could be female specifi c.9,24 
Recently, primaquine was postulated to disproportionally 
kill male gametocytes9 and thereby prevent transmission 
that depends on the presence of both male and female 
gametocytes in permissive concentrations. Methylene 
blue, another antigametocyte drug, is more potent 
against male gametocytes than against female game-
tocytes.25 It is conceivable that our quantifi cation of 
gametocytes is female-biased and becomes progressively 
more so after treatment. This could explain the absence 
of mosquito infectivity at later timepoints after 
primaquine when male gametocytes might have been 
eff ectively cleared. We tested samples with a new qRT 
PCR that detects male Pfs230p transcripts;24 however, the 
transcript levels of Pfs230p are much lower than those 
for Pfs2514 and we were unable to detect male gametocytes 
in most baseline samples (data not shown). Future 
studies should establish whether primaquine has a 
higher potency against male gametocytes and is a 
potential explanation for our fi ndings of gametocytes 
being present, yet non-infective. Findings from our study 
leave unaddressed the question of whether there is a 
diff erential eff ect of antimalarial treatment on male and 
female game tocytes. Until better indicators of gametocyte 
infectivity become available (which will probably 











(Continued from previous page)
Dark urine
Mild 0 0 0 0 1
Rhinobronchitis
Mild 0 0 1 0 0
Shortness of breath
Mild 1 0 0 0 0
Vomiting
Mild 0 1 0 0 0
Whitlow
Moderate 0 0 0 1
Joint osteoarthritis in the legs
Moderate 1 0 0 0 0
There were no severe or serious adverse events. All events were self-reported. Mild events were defi ned as those 
causing no or mlnlmal Interference with usual social and fu nctional activities; moderate events as those causing 
greater than minimaI interference; and severe events as those causing inability to perform usual social and functional 
activities. *Defi ned as probably or defi nitely related to study treatment.
Table 3: Adverse events 
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gameto cyte detection methods), the transmission-
blocking properties of antimalarial drugs can only be 
assessed by mosquito feeding assays.5,7 
The labour intensiveness of membrane feeding assays 
limits the number of sites at which trials with a 
transmission endpoint can be done and limits the study 
size that can be used. Although our study had a relatively 
small sample size, our fi ndings more than double the 
available evidence on single low doses of primaquine. 
Available recommendations are based on retrospective 
analysis of nine studies and a total of 65 individuals who 
received single low doses of primaquine in combination 
with an artemisinin-based combination therapy.7 The 
present study includes 24 009 mosquito observations 
from 284 experiments before and at three timepoints 
after single low doses of primaquine. Infectivity in our 
study was maximised through enrolment of high-density 
gametocyte carriers that are highly infectious compared 
with average malaria-infected individuals who have 
much lower gametocyte densities and are considerably 
less infectious.26 In individuals with low gametocyte 
densities, who comprise a considerable proportion of the 
human infectious reservoir for malaria,27 single low 
doses of primaquine are likely to be even more effi  cacious 
than we reported for our study population. A fraction of 
gametocyte carriers are not infectious to mosquitoes.19 In 
our study, 14 (20%) of 71 participants were not measured 
to have infectivity pre-treatment and 11 (17%) of 
them never infected mosquitoes during the whole study 
period. This failure to infect mosquitoes despite relatively 
high gametocyte densities could be caused by gametocyte 
fi tness or host factors such as naturally acquired immune 
responses to gametocyte antigens that could reduce 
transmission effi  ciency, as well as limitations of the 
membrane feeding assay.19 These factors are unlikely to 
have aff ected our comparisons of within-person changes 
in infectivity or comparisons of dose groups.
Our adaptive study design resulted in two phases of 
enrolment, the second of which was not randomised. We 
consider it unlikely that this shortcoming has aff ected our 
conclusions on the transmission-blocking properties of 
the diff erent doses of primaquine since our main analysis 
was based on within-person changes in infectivity; other 
comparisons between treatment groups were adjusted for 
baseline infectivity or baseline gametocyte density, where 
appropriate. 
Residual transmission after single low doses of prima-
quine is of particular importance considering possible 
inter individual variation in primaquine meta bolism.18 In 
our study, we successfully genotyped 53% of participants 
for cytochrome P450 2D6 (CYP2D6). This low success 
rate is a result of the availability of small volume blood 
samples that were collected for gametocyte detection and 
not for detailed human genetic analyses. One single 
participant received the highest dose of single low doses 
of primaquine tested (0·5 mg/kg) yet remained 
infectious, infecting one mosquito on day 7. CYP2D6 
typing failed for this individual; whether this participant 
was a CYP2D6 poor metaboliser is therefore unknown. 
This study was carried out in a relatively small population 
of men and boys with normal functioning G6PD in Mali. 
Thus, we are unable to generalise the fi ndings to young 
children, G6PD-defi cient people, women, and other 
African populations or people residing outside sub-
Saharan Africa, in whom G6PD variants that are associated 
with more severe G6PD enzyme defi ciency might occur. 
We chose boys and men with normal G6PD function with 
haemoglobin concentrations 80 g/L before treatment 
because their risk of haemolysis after exposure to single 
low doses of primaquine would be low. A previous study in 
Uganda showed a transient reduction in haemoglobin 
concentrations in individuals who were genotypically 
G6PD-defi cient but were screened as having normal 
functioning G6PD by fl uorescence spot test.28 We did not 
observe any signifi cant decreases in haemoglobin or 
increases in adverse events in primaquine groups 
compared with the control group. Future studies should 
address the safety profi le of single low doses of primaquine 
in larger populations that include G6PD-defi cient 
participants to inform the highest tolerable dose without 
previous testing for G6PD defi ciency. WHO recommends 
use of 0·25 mg/kg primaquine without previous G6PD 
testing in areas of low transmission or areas threatened by 
artemisinin resistance.7 However, most antimalarial drugs 
are dispensed based on age-based categories, removing the 
need to weigh patients before treatment. If single low 
doses of primaquine are to be rolled out, similar categories 
will be needed to defi ne a range of dosing that is both safe 
and effi  cacious.10 A second more challenging safety issue is 
the safety of primaquine in pregnancy.29 This issue might 
better be assessed through active pharmacovigilance of the 
use of single low doses of primaquine in programme use29 
or safety assessments of mass drug administration studies 
in which early stage pregnancies might be inadvertently 
treated and later followed-up to note pregnancy outcomes.30
Our fi ndings support WHO’s recommendation for the 
addition of one-time primaquine at a dose of 0·25 mg/kg 
in combination with dihydroartemisin–piperaquine for 
prevention of P falciparum trans mission. In community 
treatment campaigns, a simplifi ed delivery of single low 
doses of primaquine might involve age-based dosing to 
replace the current weight-based recommended dose 
regimen. This regimen could result in relative over-dosing 
and under-dosing of fractions of the population. In this 
context, our study provides valuable information on the 
dose of 0·125 mg/kg. Although not signifi cant in the 
primary analysis, in secondary analyses the 0·125mg/kg 
dose showed potent and signifi cant effi  cacy in preventing 
and reducing transmission to mosquitoes by day 2.
Further studies to assess the highest-tolerable single 
primaquine dose in G6PD-defi cient individuals are needed 
to defi ne the therapeutic range for simplifi ed delivery of 
the intervention. Community studies can then be done to 
show the impact of single low doses of primaquine on 
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malaria transmission in populations that might benefi t 
from this intervention, including in areas of low malaria 
transmission intensity.
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